What Is the PPH ETF? A Complete Guide to Returns, Expense Ratio, Holdings and Alternative ETFs
It concentrates on 25 large global pharmaceutical companies. It is a flagship pharma sector ETF that combines dividend stability with defensive characteristics.
SubscribeWhat Is This ETF?
It tracks the MVIS US Listed Pharmaceutical 25 Index and holds 25 companies with high liquidity and market capitalization among the global pharmaceutical firms listed in the United States.
It suits investors who want exposure to the long-term growth in healthcare demand driven by population aging, and who prefer dividend income and low volatility.
It is a passively managed (index-tracking) ETF launched by VanEck in 2011.
How Does It Invest?
| Item | Details |
|---|---|
| Tracked Index | MVIS US Listed Pharmaceutical 25 Index |
| Management Style | Passive (index-tracking) |
| Rebalancing Frequency | Quarterly |
| Dividend Frequency | Quarterly |
| Total Expense Ratio | 0.36% |
It selects large blue-chip companies that account for a significant share of the global pharmaceutical industry. It includes not only U.S. companies but also major foreign pharmaceutical firms listed in the U.S., tracking the performance of the global pharmaceutical market as a whole.
- High concentration in 25 core pharmaceutical stocks
- Includes a weighting in non-U.S. global big pharma
Size and Costs
Assets under management (AUM) stand at $1.1B, and the expense ratio is 0.36% per year.
Unlike the tech ETFs shown in the table, such as CLOU and SNSR, which focus on specific themes, PPH concentrates on the pharmaceutical sector, which values traditional earnings and dividends, and aims for stable portfolio management.
Performance and Trends
1-Year Price Performance
Dividend & Yield
52-Week Price RangeThe pharmaceutical sector is a classic defensive stock group and tends to hold up relatively well when market uncertainty rises. Recently, enthusiasm for innovative new drugs such as obesity treatments has driven share price gains at major companies, energizing the sector as a whole.
Long-term capital seeking both expectations for healthcare innovation and stable dividend income continues to flow in, and demand for defensive assets strengthens when recession fears emerge.
Strengths and Weaknesses
By concentrating on high-quality pharmaceutical companies, it pursues stability and growth at the same time, but it remains exposed to company-specific risks such as failed drug approvals.
💪 Key Strengths
⚠️ Points to Watch
Alternative ETFs and Related Products
While NXTG, mentioned in the table, invests in 5G technology, PPH focuses on pharmaceuticals, the tangible fruit of biotechnology. Within the pharmaceutical sector itself, alternatives include IHE, which centers on U.S. companies, and the equal-weighted XPH, and XLV, which covers healthcare broadly, is also worth considering.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 TRFK | Pacer Data and Digital Revolution ETF | $84.80 | -7.6% | $1.1B | 0.49% | 0.03% | +16.8% |
 NXTG | First Trust Indxx NextG ETF | $145.12 | -3.0% | $547.7M | 0.70% | 1.36% | +32.3% |
 CLOU | Global X Cloud Computing ETF | $28.02 | -4.2% | $413.4M | 0.68% | - | +18.4% |
 WQTM | WisdomTree Quantum Computing Fund | $26.33 | -6.0% | $309.5M | 0.45% | - | -11.9% |
 ECON | Columbia Research Enhanced Emerging Economies ETF | $32.31 | -2.6% | $297.0M | 0.47% | 1.5% | +16.0% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| LLY | Lilly(Eli) & Co | 0.39% | $1417.54 | +3.2% | $1.33T | 46.6 | 0.48% |
| NVS | Novartis AG ADR | 0.21% | $160.79 | -0.2% | $294.3B | 30.7 | 2.7% |
| MRK | Merck & Co Inc | 0.20% | $149.52 | +2.2% | $368.9B | 152.7 | 2.28% |
| NVO | Novo Nordisk ADR | 0.10% | $40.00 | +2.2% | $133.8B | 9.8 | 4.36% |
| PFE | Pfizer Inc | 0.05% | $30.52 | +1.9% | $174.0B | 40.4 | 5.65% |
| SNY | Sanofi ADR | 0.05% | $44.34 | +2.8% | $105.7B | 22.8 | 5.4% |
Investor Checkpoints
PPH is an efficient vehicle for investing in the giant pharmaceutical industry, which generates stable cash flow. Before investing, review the market environment and the product's specific features carefully using the key checklist below.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💵 Expense Level | Check cost competitiveness versus other ETFs in the sector | Top tier |
| 💊 Drug Pipeline | Review the drug development status of major holdings | Good |
| 📈 Policy Environment | Legislative trends on drug pricing in the U.S. and globally | Monitoring needed |
| 📊 Dividend Yield | Whether dividends are being maintained at the level you expect | Maintained normally |
The share price of a particular stock can swing sharply depending on the clinical results or approval status of an individual new drug. A strategy that focuses on the growth potential of the sector as a whole over the long term is needed.
It is a reasonable choice for investing in the global pharmaceutical sector, which offers stable dividends and long-term growth potential. It works well as a way to strengthen the defensive power of a core portfolio.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
Today's 5 AI picks, all free